Kiniksa Pharmaceuticals International Plc. P/E Ratio

The latest P/E ratio for KNSA is 72.97. That is above the Healthcare sector average of 25.9. Investors often review this figure alongside Kiniksa Pharmaceuticals International Plc.'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, KNSA currently prints 72.97 for P/E ratio, while the sector average sits near 25.9. That is roughly 181.8% above the sector mean. Large gaps often invite a closer look at Kiniksa Pharmaceuticals International Plc.'s growth, margins, and balance sheet.

A P/E ratio of 72.97 for Kiniksa Pharmaceuticals International Plc. is not 'good' or 'bad' on its own. Compare it with the peer average (25.9) and with KNSA's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting KNSA's P/E ratio (72.97), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Kiniksa Pharmaceuticals International Plc.'s P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.